[P4–155]: DERIVING A CUT‐OFF FOR THE ELECSYS® β‐AMYLOID (1–42) IMMUNOASSAY FOR USE IN CLINICAL TRIALS SUPPORTED BY ELI LILLY FOR PATIENTS WITH CLINICALLY DEFINED ALZHEIMER's DISEASE (AD). (1st July 2017)